Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 5/20 | 0.61 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.48 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.48 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7322310 | 0.83 | KCNJ6 (0.52) | CRACR2AORAI1MAPK13TRPC1TRPC3 | |
| SCHEMBL7320670 | 0.81 | MAPK14 (0.54) | MAPK13MAPK14MAPK12MAPK11CCNC | |
| SCHEMBL7326362 | 0.81 | CRACR2A (0.66) | CRACR2AORAI1EPHX2TRPC1TRPC3 | |
| SCHEMBL7322557 | 0.80 | ORAI1 (0.77) | CRACR2AORAI1EPHX2TRPC1TRPC3 | |
| SCHEMBL6815524 | 0.78 | NAMPT (0.71) | NAMPTCYP17A1 | |
| SCHEMBL7326898 | 0.78 | MAPK14 (0.52) | MAPK14CCNCCDK8 | |
| SCHEMBL7321672 | 0.77 | CRACR2A (0.64) | CRACR2AORAI1EPHX2TRPC1TRPC3 | |
| SCHEMBL7321677 | 0.76 | CRACR2A (0.66) | CRACR2AORAI1EPHX2TRPC1TRPC3 | |
| SCHEMBL7314961 | 0.76 | ORAI1 (0.77) | CRACR2AORAI1EPHX2TRPC1TRPC3 | |
| SCHEMBL1667929 | 0.76 | CRACR2A (1.00) | CRACR2AORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
| EP-1068187-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051580-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | CRACR2A 3286/4885ORAI1 3522/4885MAPK13 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.